[18F]FDG-PET-Based Personalized Radiotherapy Dose Prescription

PET imaging with 2'-deoxy-2'-[18F]fluoro-D-glucose ([18F]FDG) has become one of the pillars in the management of malignant diseases. It has proven value in diagnostic workup, treatment policy, follow-up, and as prognosticator for outcome. [18F]FDG is widely available and standards have been developed for PET acquisition protocols and quantitative analyses. More recently, [18F]FDG-PET is also starting to be appreciated as a decision aid for treatment personalization. This review focuses on the potential of [18F]FDG-PET for individualized radiotherapy dose prescription. This includes dose painting, gradient dose prescription, and [18F]FDG-PET guided response-adapted dose prescription. The current status, progress, and future expectations of these developments for various tumor types are discussed.Semin Radiat Oncol 33:287-297 & COPY; 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/ licenses/by/4.0/)

Automated summary

PET imaging with [18F]FDG-PET has proven value in the management of malignant diseases, and has potential for individualized radiotherapy dose prescription. This review discusses the current status, progress, and future expectations of [18F]FDG-PET in individualized radiotherapy for various tumor types.